Ocrevus: Half of Black and Hispanic adults had no MS activity

Credibility

Interest

Share:1 min read

Key Takeaway

After 48 weeks on Ocrevus, about half of Black and Hispanic adults with relapsing MS had no signs of disease activity.

What They Found

The study followed Black and Hispanic adults with relapsing MS who received ocrelizumab (Ocrevus). After 48 weeks, about half had no relapses, disability worsening, or new activity on brain scans. About 95% had no relapse, and about 95% had no confirmed disability worsening. About 8% had serious health problems during the study, and about 2% stopped treatment. Reactions during treatment were more common among Hispanic participants, while digestive problems were more common among Black participants.

Who Should Care and Why

The study included Black and Hispanic adults with relapsing MS. These groups have been underrepresented in MS treatment research. Participants received Ocrevus for two years. Researchers tracked relapses, disability worsening, brain scan changes, and health problems during treatment. The results describe what happened in these groups, but the study did not compare Ocrevus with another treatment.

Important Considerations

You should know this trial included 182 people, and everyone received Ocrevus. You cannot tell from this study how their results compare with people taking another treatment or no treatment. Although treatment lasted two years, the main disease activity result reported here was measured at 48 weeks.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Clinical Trials Treatment Updates

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News